SCHEMBL17454490

SCHEMBL17454490

CC(=O)c1cnn2c(C3CC3)c(O)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 2/20 0.40
▸ NFE2L2 Q16236 2/20 0.40
▸ PLAT P00750 1/20 0.39
▸ SPR P35270 3/20 0.37
▸ ALDH1A1 P00352 5/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ SLC9A1 P19634 1/20 0.35
▸ SLC9A2 Q9UBY0 1/20 0.35
▸ MAPK1 P28482 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ GAA P10253 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ CREBBP Q92793 1/20 0.33
▸ QDPR P09417 1/20 0.33
▸ UBE2M P61081 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452657 0.85 KEAP1 (0.38) KEAP1NFE2L2PLATSPRALDH1A1
SCHEMBL20229595 0.85 PLAT (0.43) KEAP1NFE2L2PLATSPRALDH1A1
SCHEMBL17437928 0.85 SPR (0.49) KEAP1NFE2L2PLATSPRALDH1A1
SCHEMBL21946619 0.80 BRD4 (0.42) KEAP1NFE2L2CREBBP
SCHEMBL21947204 0.76 ROCK2 (0.39) ROCK2
SCHEMBL17454370 0.75 ROCK2 (0.55) ROCK2
SCHEMBL21948611 0.75 ROCK2 (0.38) SPRKDM4EROCK2
SCHEMBL21947361 0.74 ROCK2 (0.38) ROCK2
SCHEMBL17454424 0.74 MAPT (0.46) KEAP1NFE2L2PLATALDH1A1TDP1
SCHEMBL23889037 0.73 ROCK2 (0.41) PLATROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 KEAP1 247/4885NFE2L2 1220/4885PLAT 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback